Immunological and virological features of combined secondary diseases in patients with HIV-based immunodeficiency

Introduction. The HIV epidemic situation in the Russian Federation remains tense. Low coverage of antiretroviral therapy (ART) contributes to the disease progression in some PLHIV. Many authors point to a high prevalence of different secondary disease combinations.

Objective. Studying the structure of secondary disease combinations in inpatients and identifying features of immunological and virological indicators.

Materials and methods. There was retrospective analysis of 1440 cases of HIV-infected admission in ICU SBHI «ICH № 2» DZM in 2018–2020. The number of CD4+ cells were estimated in 1185 patients, viral load (VL) is defined in 1173 patients.

Statistical analysis is held, using program StatTech v. 2.6.2 (developer — LLC «Statech», Russia).

Results. 18,5% of patients had 1 secondary disease, 75,9% were diagnosed a combination of 2 and more various lesions. 275 different combinations of secondary diseases are recorded: from 50 combinations of 2 secondary lesions to 4 combinations of 7 nosological units. Ме VL in patients with no secondary diseases — 13 303 copies/ml, with 1 secondary disease it increased 3,2 times (42 926) (p<0,001). Similar changes are detected with 3, 5 and 6 diseases. Ме number of CD4+ lymphosytes in the absence of a secondary pathology — 223 cells/mcl. As the number of secondary diseases increases from 1 to 4, we observe consistent reduction in the number of CD4+ lymphosytes; in a combined secondary pathology Ме CD4+ cells did not exceed 100 cells; with 4 and more secondary diseases this figure did not exceed 20 cells in mcl. Correlation analysis of CD4+ cells and the number of combined secondary diseases revealed the presence of moderate connection tightness on the Chaddock scale (r_xy=0,356, p<0,001). The depth of immunodeficiency also affects the outcome of the disease: (M±SD) CD4+ cells in the group of the dead were 101±153 (95% DI: 91–112), in the group of survivors — 198±226 (95% DI:172–224; p<0,001).

Conclusion. Combined secondary disease among patients of ICU infectious hospital were diagnosed in 75.9% patients. There were differences by VL level which increased with the growth of combined lesion number; more significant correlation was found between the amount of CD4+ cells and the number of secondary diseases. The obtained results are confirmed by reduced likelihood of a favorable outcome of the disease with increasing number of combined secondary diseases.

1. Kravchenko A.V., Ladnaya N.N., Kozyrina N.V., Pokrovskij V.V., Yurin O.G., Sokolova E.V., Dement’eva L.A. Causes of deaths among people infected with HIV in the Russian Federation in 2008–2018. Epidemiology and infectious diseases. Current issues, 2020, Vol. 10, No. 3, рр. 63–69 (In Russ.).

2. Leonova O.N., Stepanova E.V., Belyakov N.A. Severe and comorbid conditions in patients with HIV infection: An analysis of adverse outcomes. HIV Infection and Immunosuppressive Disorders. 2017, Vol. 9, No. 1, рр. 55–64 (In Russ.).

3. Musatov V.B., Yаkubenko A.L., Tyrgina T.V. Late-detected cases of HIV infection among hospitalized patients. HIV Infection and Immunosuppressive Disorders, 2010, Vol. 2, No. 3, рр. 88–90 (In Russ.).

4. Pokrovskaya A.V., Pokrovskij V.V., Akimkin V.G. The possibility of using a cascade model of medical care for people living with HIV. Therapeutic archive, 2020, Vol. 92, No. 11, рр. 71–76. doi: 10.26442/00403660.2020.11.000686 (In Russ.).

5. Shahgil’dyan V.I., Yаdrihinskaya M.S., Safonova A.P., Domonova E.A., Shipulina O.Y.U., Al’vares-Figeroa M.V., Dolgova E.A., Tishkevich O.A. The structure of secondary diseases and modern approaches to their laboratory diagnosis in patients with HIV infection. Epidemiology and infectious diseases. Current issues, 2015, Vol. 1, рр. 24–30 (In Russ.).

6. Solomon F.B., Angore B.N., Koyra H.C., Tufa E.G., Berheto T.M., Admasu M. Spectrum of opportunistic infections and associated factors among people living with HIV/AIDS in the era of highly active anti-retroviral treatment in Dawro Zone hospital: a retrospective study // BMC Res Notes. 2018. Aug. 2020. Vol. 11, No. 1. Р. 604. doi: 10.1186/s13104-018-3707-9. PMID: 30126450; PMCID: PMC6102885.

7. Medina N., Alastruey-Izquierdo A., Mercado D., Bonilla O., Pérez JC., Aguirre L., Samayoa B., Arathoon E., Denning D.W., Rodriguez-Tudela J.L. Fungired. Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIV // AIDS. 2020. Sep. 1. Vol. 34, No. 11. Р. 1625–1632. doi: 10.1097/QAD.0000000000002631. PMID: 32694415.

8. Patel S., Kinariwala D., Javadekar T. Clinico-microbiological study of opportunistic infection in HIV seropositive patients // Indian Journal of Sexually Transmitted Diseases. 2011. Vol. 32, No. 2. Р. 90–93. doi: 10.4103/0253-7184.85411.

9. Okeahialam B.N., Sani M.U. Heart disease in HIV/AIDS. How much is due to cachexia? // Afr. J. Med. Med. Sci. 2006. Dec. Vol. 35, Suppl. Р. 99–102. PMID: 18050781.

10. De Leon Ch.R.V., Chiu Н.Н.С., De Castro Р.В., Velasquez J.R.H., Dans A.М.L. Racecadotril (Acetorphan) for Diarrhea in Adults Infected with HIV/AIDS: A Meta-Analysis and Systematic Review // Acta Medica Philippina. 2020. Vol. 54, No. 3. Р. 313–319. doi: https://doi.org/10.47895/amp.v54i3.1675.

11. Kaplan J.E., Benson C., Holmes K.K., Brooks J.T., Pau A., Masur H.; Centers for Disease Control and Prevention (CDC); National Institutes of Health; HIV Medicine Association of the Infectious Diseases Society of America. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America // MMWR Recomm Rep. 2009. Apr. 10. Vol. 58, No. RR-4. Р. 1–207; quiz CE1–4. PMID: 19357635.

12. Ryom L., Cotter A., De Miguel R., Béguelin C., Podlekareva D., Arribas J.R., Marzolini C., Mallon P., Rauch A., Kirk O., Molina J.M., Guaraldi G., Winston A., Bhagani S., Cinque P., Kowalska J.D., Collins S., Battegay M.; EACS Governing Board. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0 // HIV Med. 2020. Nov. Vol. 21, No. 10. Р. 617–624. doi: 10.1111/hiv.12878. Epub 2020 Sep 3. PMID: 32885559; PMCID: PMC7754379.

13. Eneh P.C., Hullsiek K.H., Kiiza D., Rhein J., Meya D.B., Boulware D.R., Nicol M.R. Prevalence and nature of potential drug-drug interactions among hospitalized HIV patients presenting with suspected meningitis in Uganda // BMC Infect Dis. 2020. Aug. 5. Vol. 20, No. 1. Р. 572. doi: 10.1186/s12879-020-05296-w. PMID: 32758158; PMCID: PMC7405463.

14. Pokrovskij V.V., Yurin O.G., Kravchenko A.V., Belyaeva V.V., Buravcova V.V., Deulina M.O., Ermak T.N., Efremova O.S., Kanestri V.G., Kozyrina N.V., Ladnaya N.N., Narsiya R.S., Shahgil’dyan V.I., Kuimova U.A., Pokrovskaya A.V., Popova A.A., Hohlova O.N. Recommendations for the treatment of HIV infection and related diseases, chemoprophylaxis of HIV infection. Epidemiology and infectious diseases. Current issues, 2020, Vol. 10, No. S4, рр. 1–91 (In Russ.).